DPX RSV Vaccine
Alternative Names: DepoVax™; DPX-based RSV Vaccine; DPX-RSV (A); DPXRSV; Respiratory syncytial virus vaccineLatest Information Update: 03 Feb 2025
At a glance
- Originator Immunovaccine
- Developer IMV
- Class Respiratory syncytial virus vaccines; Viral vaccines
- Mechanism of Action Immunostimulants; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Respiratory syncytial virus infections
Most Recent Events
- 17 Jan 2025 Phase-I development in Respiratory-syncytial-virus-infections (Prevention) in Canada (Parenteral)
- 28 Sep 2024 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(Prevention, In volunteers) in Canada (Parenteral)
- 28 Aug 2024 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(Prevention, In volunteers) in Canada (Parenteral)